Company Analysis
Sign in

Novartis AG (NVS)

NYSE: NVS · Pharmaceutical Preparations · Basel, CH · filing with the SEC since 2001
Full chart Alerts Compare
Grade5.5
◀ Past 6.9● Present 6.1▶ Future 3.2
6 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenuen/a
Net income$13.97B+17.0%
Earnings per share$7.15+21.8%
Operating cash flow$19.14B+8.7%
Cash$11.44B-0.2%
Debt$28.73B+16.2%
Shareholders’ equity$46.55B+5.5%
Shares, diluted1.96B-3.9%
Return on equity30.0%
The recordfrom its filings
Filings in 202631
Newest filingNov 12 · 6-K
Annual reportFeb 4, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted3,941
Filer categoryLarge accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
Nov 9, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton NVS · research, not advice